Pembrolizumab-associated tumor development in a patient with Sézary syndrome.

Stephen J Malachowski, Leigh A Hatch, Lubomir Sokol, Jane Messina, Lucia Seminario-Vidal

Abstract readCase Reports

In one paragraph

Article in JAAD case reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it

0cells of the map it votes in

4citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

Abrupt progression from patch- to tumor-stage mycosis fungoides following pembrolizumab treatment.JAAD case reports · 2024
Article
Unleashed monocytic engagement in Sézary syndrome during the combination of anti-CCR4 antibody with type I interferon.Blood advances · 2024
Article
Interleukin-15 augments NK cell-mediated ADCC of alemtuzumab in patients with CD52+ T-cell malignancies.Blood advances · 2023
Article
Reduction of T Lymphoma Cells and Immunological Invigoration in a Patient Concurrently Affected by Melanoma and Sezary Syndrome Treated With Nivolumab.Frontiers in immunology · 2020
Article

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Stephen J MalachowskiDepartment of Dermatology, Morsani College of Medicine, University of South Florida, Tampa, Florida.

Leigh A HatchDepartment of Dermatology, Morsani College of Medicine, University of South Florida, Tampa, Florida.

Lubomir SokolDepartment of Malignant Hematology, Moffitt Center and Research Institute, Tampa, Florida.

Jane MessinaDepartment of Anatomic Pathology, Moffitt Center and Research Institute, Tampa, Florida.

Lucia Seminario-VidalDepartment of Dermatology, Morsani College of Medicine, University of South Florida, Tampa, Florida.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

BSA, body surface areaCTCL, cutaneous T-cell lymphomacutaneous T-cell lymphomaECP, extracorporeal photopheresisimmunotherapyPD-1, programmed cell death-1pembrolizumabSézary syndromeSS, Sézary syndrome

Identifiers

PMID31909130

DOI10.1016/j.jdcr.2019.11.005

PMCPMC6938917

What OpenQuestion holds

Textmetadata

LicenceCC BY-NC-ND

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.